Ubs Asset Management Americas Inc Gossamer Bio, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.74 - $12.87 $10,560 - $78,108	6,069 Added 12.66%	54,020 $117,000
Q4 2021 Feb 14, 2022	SELL	$10.12 - $14.07 $18,124 - $25,199	-1,791 Reduced 3.6%	47,951 $542,000
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $39,280 - $47,872	-4,910 Reduced 8.98%	49,742 $403,000
Q1 2021 May 14, 2021	BUY	$8.63 - $10.94 $105,286 - $133,468	12,200 Added 28.74%	54,652 $505,000
Q4 2020 Mar 01, 2021	SELL	$8.3 - $13.59 $62,250 - $101,925	-7,500 Reduced 15.01%	42,452 $410,000
Q3 2020 Nov 13, 2020	BUY	$11.3 - $14.75 $77,970 - $101,775	6,900 Added 16.03%	49,952 $619,000
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $303,231 - $508,994	31,852 Added 284.39%	43,052 $559,000
Q1 2020 May 15, 2020	BUY	$8.0 - $15.48 $89,600 - $173,376	11,200 New	11,200 $113,000

112

168M

450K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $99.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.